• Please log in or register to access this feature.

Original Research

You have full text access to this OnlineOpen article

Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

  1. Susanne Bäck1,*,
  2. Johan Peränen2,
  3. Emilia Galli2,3,
  4. Päivi Pulkkila2,
  5. Liina Lonka-Nevalaita2,
  6. Tuulia Tamminen1,
  7. Merja H. Voutilainen1,
  8. Atso Raasmaja1,
  9. Mart Saarma2,
  10. Pekka T. Männistö1,
  11. Raimo K. Tuominen1

Article first published online: 14 JAN 2013

DOI: 10.1002/brb3.117

Issue

Brain and Behavior

Brain and Behavior

Volume 3, Issue 2, pages 75–88, March 2013

Total views since publication: 449

Additional Information

How to Cite

Bäck, S., Peränen, J., Galli, E., Pulkkila, P., Lonka-Nevalaita, L., Tamminen, T., Voutilainen, M. H., Raasmaja, A., Saarma, M., Männistö, P. T. and Tuominen, R. K. (2013), Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain and Behavior, 3: 75–88. doi: 10.1002/brb3.117

Author Information

  1. 1

    Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

  2. 2

    Institute of Biotechnology, University of Helsinki, Helsinki, Finland

  3. 3

    Division of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

* Correspondence
Susanne Bäck, Division of Pharmacology and Toxicology, Faculty of Pharmacy, P.O. Box 56 (Viikinkaari 5E), 00014 University of Helsinki, Finland. Tel: +358-9-191-59458; Fax: +358-9-191-59471; E-mail: susanne.back@helsinki.fi

Publication History

  1. Issue published online: 14 MAR 2013
  2. Article first published online: 14 JAN 2013
  3. Manuscript Accepted: 16 DEC 2012
  4. Manuscript Revised: 29 NOV 2012
  5. Manuscript Received: 27 AUG 2012

Funded by

  • Network of European Funding for Neuroscience Research (ERA-Net NEURON)
  • Academy of Finland. Grant Number: 253840
  • EU FR7 MolPark
  • Finnish Cultural Foundation
  • Finnish Parkinson Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (3747K)

References

  • Ai, Y., W. Markesbery, Z. Zhang, R. Grondin, D. Elseberry, G. A. Gerhardt, et al. 2003. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 461:250–261.
    Direct Link:
  • Airavaara, M., B. K. Harvey, M. H. Voutilainen, H. Shen, J. Chou, P. Lindholm, et al. 2012. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. 21:1213–1223.
  • Bartus, R. T., C. D. Herzog, Y. Chu, A. Wilson, L. Brown, J. Siffert, et al. 2011. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26:27–36.
    Direct Link:
  • Björklund, T., and J. H. Kordower. 2010. Gene therapy for Parkinson's disease. Mov. Disord. 25(Suppl. 1):S161–S173.
    Direct Link:
  • Blanchard, V., P. Anglade, G. Dziewczapolski, M. Savasta, Y. Agid, and R. Raisman-Vozari. 1996. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res. 709:319–325.
  • Burger, C., O. S. Gorbatyuk, M. J. Velardo, C. S. Peden, P. Williams, S. Zolotukhin, et al. 2004. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10:302–317.
  • Choi-Lundberg, D. L., Q. Lin, T. Schallert, D. Crippens, B. L. Davidson, Y. N. Chang, et al. 1998. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154:261–275.
  • Ciesielska, A., G. Mittermeyer, P. Hadaczek, A. P. Kells, J. Forsayeth, and K. S. Bankiewicz. 2011. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 19:922–927.
  • Dauer, W., and S. Przedborski. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889–909.
  • Decressac, M., A. Ulusoy, B. Mattsson, B. Georgievska, M. Romero-Ramos, D. Kirik, et al. 2011. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain 134:2302–2311.
  • Doucet, G., L. Descarries, and S. Garcia. 1986. Quantification of the dopamine innervation in adult rat neostriatum. Neuroscience 19:427–445.
  • Eslamboli, A., R. M. Cummings, R. M. Ridley, H. F. Baker, N. Muzyczka, C. Burger, et al. 2003. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184:536–548.
  • Fallon, J. H., and S. E. Loughlin. 1995. Substantia nigra. Pp. 215–237 in G. Paxinos, ed. The rat nervous system. Academic Press, San Diego, CA.
  • Gash, D. M., Z. Zhang, A. Ovadia, W. A. Cass, A. Yi, L. Simmerman, et al. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252–255.
  • Gasmi, M., E. P. Brandon, C. D. Herzog, A. Wilson, K. M. Bishop, E. K. Hofer, et al. 2007a. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol. Dis. 27:67–76.
  • Gasmi, M., C. D. Herzog, E. P. Brandon, J. J. Cunningham, G. A. Ramirez, E. T. Ketchum, et al. 2007b. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol. Ther. 15:62–68.
  • Georgievska, B., D. Kirik, and A. Björklund. 2002a. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177:461–474.
  • Georgievska, B., D. Kirik, C. Rosenblad, C. Lundberg, and A. Björklund. 2002b. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. NeuroReport 13:75–82.
  • Gill, S. S., N. K. Patel, G. R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, et al. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9:589–595.
  • Hellman, M., U. Arumäe, L. Y. Yu, P. Lindholm, J. Peränen, M. Saarma, et al. 2011. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J. Biol. Chem. 286:2675–2680.
  • Herzog, C. D., B. Dass, J. E. Holden, J. Stansell III, M. Gasmi, M. H. Tuszynski, et al. 2007. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov. Disord. 22:1124–1132.
    Direct Link:
  • Hoffer, B. J., A. Hoffman, K. Bowenkamp, P. Huettl, J. Hudson, D. Martin, et al. 1994. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:107–111.
  • Johnston, L. C., J. Eberling, P. Pivirotto, P. Hadaczek, H. J. Federoff, J. Forsayeth, et al. 2009. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene Ther. 20:497–510.
  • Kaplitt, M. G., A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor, et al. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097–2105.
  • Kearns, C. M., and D. M. Gash. 1995. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:104–111.
  • Kirik, D., C. Rosenblad, and A. Björklund. 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:259–277.
  • Kirik, D., C. Rosenblad, A. Björklund, and R. J. Mandel. 2000. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20:4686–4700.
  • Kirik, D., B. Georgievska, and A. Björklund. 2004. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7:105–110.
  • Kordower, J. H., M. E. Emborg, J. Bloch, S. Y. Ma, Y. Chu, L. Leventhal, et al. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767–773.
  • Kordower, J. H., C. D. Herzog, B. Dass, R. A. Bakay, J. Stansell III, M. Gasmi, et al. 2006. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 60:706–715.
    Direct Link:
  • Lang, A. E., S. Gill, N. K. Patel, A. Lozano, J. G. Nutt, R. Penn, et al. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59:459–466.
    Direct Link:
  • LeWitt, P. A., A. R. Rezai, M. A. Leehey, S. G. Ojemann, A. W. Flaherty, E. N. Eskandar, et al. 2011. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10:309–319.
  • Lindholm, P., and M. Saarma. 2010. Novel CDNF/MANF family of neurotrophic factors. Dev. Neurobiol. 70:360–371.
  • Lindholm, P., M. H. Voutilainen, J. Lauren, J. Peränen, V. M. Leppänen, J. O. Andressoo, et al. 2007. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448:73–77.
  • Lonka-Nevalaita, L., M. Lume, S. Leppänen, E. Jokitalo, J. Peränen, and M. Saarma. 2010. Characterization of the intracellular localization, processing, and secretion of two glial cell line-derived neurotrophic factor splice isoforms. J. Neurosci. 30:11403–11413.
  • Marks, W. J., Jr., J. L. Ostrem, L. Verhagen, P. A. Starr, P. S. Larson, R. A. Bakay, et al. 2008. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7:400–408.
  • Marks, W. J., Jr., R. T. Bartus, J. Siffert, C. S. Davis, A. Lozano, N. Boulis, et al. 2010. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9:1164–1172.
  • McCown, T. J. 2005. Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 5:333–338.
  • Nutt, J. G., K. J. Burchiel, C. L. Comella, J. Jankovic, A. E. Lang, E. R. Laws Jr., et al. 2003. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69–73.
  • Palgi, M., R. Lindström, J. Peränen, T. P. Piepponen, M. Saarma, and T. I. Heino. 2009. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc. Natl. Acad. Sci. USA 106:2429–2434.
  • Parkash, V., P. Lindholm, J. Peränen, N. Kalkkinen, E. Oksanen, M. Saarma, et al. 2009. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng. Des. Sel. 22:233–241.
  • Paterna, J. C., J. Feldon, and H. Bueler. 2004. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J. Virol. 78:6808–6817.
  • Paxinos, G., and C. Watson. 1997. The rat brain in stereotaxic coordinates. Academic Press, San Diego, CA.
  • Petrova, P., A. Raibekas, J. Pevsner, N. Vigo, M. Anafi, M. K. Moore, et al. 2003. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 20:173–188.
  • Petrova, P. S., A. Raibekas, J. Pevsner, N. Vigo, M. Anafi, M. K. Moore, et al. 2004. Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog. Brain Res. 146:168–183.
  • Ramaswamy, S., K. E. Soderstrom, and J. H. Kordower. 2009. Trophic factors therapy in Parkinson's disease. Prog. Brain Res. 175:201–216.
  • Robinson, T. E., Z. Mocsary, D. M. Camp, and I. Q. Whishaw. 1994. Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J. Neurosci. 14:2687–2696.
  • Sherer, T. B., B. K. Fiske, C. N. Svendsen, A. E. Lang, and J. W. Langston. 2006. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21:136–141.
    Direct Link:
  • Slevin, J. T., G. A. Gerhardt, C. D. Smith, D. M. Gash, R. Kryscio, and B. Young. 2005. Improvement of bilateral motor functions in patients with Parkinson's disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102:216–222.
  • Tomac, A., E. Lindqvist, L. F. Lin, S. O. Ogren, D. Young, B. J. Hoffer, et al. 1995a. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335–339.
  • Tomac, A., J. Widenfalk, L. F. Lin, T. Kohno, T. Ebendal, B. J. Hoffer, et al. 1995b. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. USA 92:8274–8278.
  • Voutilainen, M. H., S. Bäck, E. Pörsti, L. Toppinen, L. Lindgren, P. Lindholm, et al. 2009. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J. Neurosci. 29:9651–9659.
  • Voutilainen, M. H., S. Bäck, J. Peränen, P. Lindholm, A. Raasmaja, P. T. Männistö, et al. 2011. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp. Neurol. 228:99–108.
  • Zhang, Z., Y. Miyoshi, P. A. Lapchak, F. Collins, D. Hilt, C. Lebel, et al. 1997. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 282:1396–1401.
View Full Article (HTML) Get PDF (3747K)